Maruno K
Second Department of Surgery, Tokyo Medical and Dental University School of Medicine, Japan.
Nihon Geka Gakkai Zasshi. 1990 Jun;91(6):760-5.
A sensitive radioimmunoassay (RIA) system for plasma gastrin-releasing peptide (GRP) was developed using immune-affinity chromatography for plasma extraction. Plasma neuron-specific enolase (NSE) levels were determined by use of RIA without extraction. Plasma GRP levels in 12 control subjects were (mean +/- SD) 1.2 +/- 0.26pg/ml. Plasma GRP levels were elevated at frequencies of 79% in untreated patients with small cell lung carcinoma (SCLC). The levels in 21 patients with non-SCLC were not elevated. In nine of 10 patients with complete response (CR) or partial response (PR), plasma GRP levels decreased significantly when the patients were judged to have achieved CR or PR. In four patients with progressive disease (PD), the levels were elevated after treatment when compared with levels before treatment. In six of 10 patients with CR or PR, plasma NSE levels decreased significantly at the judgment of CR or PR. In two of four patients with PD, the levels were elevated after treatment. Furthermore, changes in plasma GRP level showed more excellent correlation with the therapeutic response than changes in plasma NSE level in the clinical courses of two patients with CR and a patient with PD. These results suggest that the plasma GRP level could be a useful tumor marker in SCLC patients.
利用免疫亲和层析法提取血浆，开发了一种用于检测血浆胃泌素释放肽（GRP）的灵敏放射免疫分析（RIA）系统。血浆神经元特异性烯醇化酶（NSE）水平采用无需提取的RIA法测定。12名对照受试者的血浆GRP水平为（均值±标准差）1.2±0.26 pg/ml。小细胞肺癌（SCLC）未治疗患者中，血浆GRP水平升高的频率为79%。21名非SCLC患者的血浆GRP水平未升高。在10名完全缓解（CR）或部分缓解（PR）的患者中，有9名患者在判定达到CR或PR时，血浆GRP水平显著下降。在4名疾病进展（PD）的患者中，治疗后血浆GRP水平较治疗前升高。在10名CR或PR患者中的6名，判定CR或PR时血浆NSE水平显著下降。在4名PD患者中的2名，治疗后血浆NSE水平升高。此外，在2名CR患者和1名PD患者的临床病程中，血浆GRP水平的变化与治疗反应的相关性比血浆NSE水平的变化更显著。这些结果表明，血浆GRP水平可能是SCLC患者有用的肿瘤标志物。
